Tardive Dyskinesia: Treatment Update
AbstractPurpose of ReviewTardive dyskinesia (TD) is caused by exposure to medications with dopamine antagonism, mainly antipsychotics. It often distresses individuals, physically and emotionally and affects their quality of life. We evaluated peer-reviewed recently published articles with a goal of providing a critically appraised update on the latest advancements in this field.Recent FindingsIn 2017, FDA approved VMAT2 inhibitors, deutetrabenazine and valbenazine. They have demonstrated efficacy in several class 1 studies. Also there have been update in the evidence-based guidelines for treatment for tardive dyskinesia.SummaryVarious medication classes are being used for treatment of TD with VMAT2 inhibitors to be first FDA-approved medications. Their use should be tailored to the individual patient. Long-term studies will further guide us in how to optimize treatment, especially in the real-world setting. As clinicians, we need to take into consideration all aspects of symptomatology, etiology, potential side effects of the medications, to find the best possible “match” for our patients.
Cholecystokinin stimulated HIDA (CCK-HIDA) has been used to identify patients with biliary dyskinesia and select patients likely to benefit from cholecystectomy. The appropriate use of this study in children remains controversial and this study aims to better understand the utility of this test.
ConclusionsCyclophosphamide should be considered for nonresponders to first ‐line immunotherapy.
Authors: Artukoglu BB, Li F, Szejko N, Bloch MH Abstract OBJECTIVE: To examine the efficacy of pharmacologic treatments for tardive dyskinesia (TD). DATA SOURCES: PubMed was searched on December 12, 2017, for randomized, placebo-controlled trials examining the treatment of TD using the search terms (drug-induced dyskinesia OR tardive dyskinesia) AND (psychotic disorders OR schizophrenia). STUDY SELECTION: Studies were included if they examined tardive dyskinesia treatment as the primary outcome and were randomized and placebo-controlled trials. DATA EXTRACTION: The effect size (standard mean difference)...
Parkinson's disease (PD) patients develop levodopa induced dyskinesia with disease progression from sensitization of central pathways. Pain pathways are also impacted with suggestions dyskinetic patients may process pain differently.
AbstractIntroductionWe investigated if uptake pattern on myocardial perfusion SPECT (MPS) in patients with left bundle branch block (LBBB) is related to myocardial fibrosis, myocardial wall motion, and electrocardiography (ECG) characteristics.MethodsTwenty-three patients (9 women) with LBBB, examined with MPS and cardiac magnetic resonance (CMR), were included. Tracer uptake on MPS was classified by visual interpretation as typical LBBB pattern (Defect+, n = 13) or not (Defect−, n = 10) and quantitatively. CMR images were evaluated for wall thickness and for myocardial wall motion both b...
Publication date: Available online 20 May 2020Source: Stem Cell ResearchAuthor(s): Nora Drick, Julia Dahlmann, Anais Sahabian, Alexandra Haase, Gudrun Göhring, Nico Lachmann, Felix C. Ringshausen, Tobias Welte, Ulrich Martin, Ruth Olmer
Authors: PMID: 32425619 [PubMed]
In patients with Parkinson's disease (PD), pulsatile dopaminergic stimulation may be a primary cause of levodopa-induced dyskinesia (LID). We aimed to investigate the correlation between levodopa pharmacokinetics (PK) and LID in PD.
Publication date: Available online 18 May 2020Source: Stem Cell ResearchAuthor(s): Julia Dahlmann, Anais Sahabian, Nora Drick, Alexandra Haase, Gudrun Göhring, Nico Lachmann, Felix C. Ringshausen, Tobias Welte, Ulrich Martin, Ruth Olmer
In case you were ever stupid enough to follow Trump’s lead you would have already injected ultraviolets in your eyeballs by now to save you from Covid and maybe bathed in Domestos or sulfuric acid or both! Anyway, his latest bullshine claim is that he’s been taking the antimalarial drug hydroxychloroquine to keep Covid at bay. Well, for starters there is no evidence that this drug acts as a prophylactic against infection with SARS CoV-2 or indeed any pathogen other than the causative agent of otherwise drug-resistant malaria. It’s primary use is in treating lupus. There was some testing done weeks ago to...